Thursday, September 11, 2025 12:16:19 PM
ANSWER to delisting process.
For a stock trading below $1, NASDAQ issues a deficiency notice after 30 consecutive business days and generally allows a company up to 360 days to regain compliance before starting delisting procedures. Recent rule changes in early 2025 created stricter circumstances that can accelerate this timeline significantly.
NASDAQ delisting timeline
30 consecutive business days below $1: If a company's closing bid price is below $1 for 30 consecutive business days, NASDAQ sends the company a notice of non-compliance.
Initial 180-day grace period: The company has 180 calendar days from the deficiency notice date to fix the issue. To regain compliance, the closing bid price must be $1 or higher for at least 10 consecutive business days during this period.
Potential second 180-day grace period: After the first period expires, a company may be eligible for a second 180-day grace period. This is often available to companies on the Nasdaq Capital Market if they meet other listing requirements and notify NASDAQ of their intent to regain compliance.
Immediate suspension after 360 days: Under new rules approved in early 2025, if a company fails to regain compliance after the second 180-day grace period (a total of 360 days), it will face immediate suspension and delisting. A request for a hearing will no longer automatically stay the delisting process, and the stock would trade over-the-counter during any appeal.
For a stock trading below $1, NASDAQ issues a deficiency notice after 30 consecutive business days and generally allows a company up to 360 days to regain compliance before starting delisting procedures. Recent rule changes in early 2025 created stricter circumstances that can accelerate this timeline significantly.
NASDAQ delisting timeline
30 consecutive business days below $1: If a company's closing bid price is below $1 for 30 consecutive business days, NASDAQ sends the company a notice of non-compliance.
Initial 180-day grace period: The company has 180 calendar days from the deficiency notice date to fix the issue. To regain compliance, the closing bid price must be $1 or higher for at least 10 consecutive business days during this period.
Potential second 180-day grace period: After the first period expires, a company may be eligible for a second 180-day grace period. This is often available to companies on the Nasdaq Capital Market if they meet other listing requirements and notify NASDAQ of their intent to regain compliance.
Immediate suspension after 360 days: Under new rules approved in early 2025, if a company fails to regain compliance after the second 180-day grace period (a total of 360 days), it will face immediate suspension and delisting. A request for a hearing will no longer automatically stay the delisting process, and the stock would trade over-the-counter during any appeal.
Recent IXHL News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/15/2026 01:29:02 PM
- Incannex Healthcare Officially Commences DReAMzz Clinical Study for IHL-42X in Obstructive Sleep Apnea • GlobeNewswire Inc. • 05/14/2026 02:35:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/14/2026 11:30:31 AM
- Incannex Healthcare Wins MedTech Breakthrough Award for IHL-42X, Underscoring Leadership in Next-Generation Drug Development • GlobeNewswire Inc. • 05/12/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/12/2026 11:30:21 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/22/2026 12:00:44 PM
- Incannex Healthcare PSX-001 Program Aligns with White House Executive Order Accelerating Access to Psychedelic Treatments for Serious Mental Illness • GlobeNewswire Inc. • 04/22/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 12:00:23 PM
- Incannex Reactivates Share Repurchase Program, Underscoring Confidence in Valuation and Strategic Position • GlobeNewswire Inc. • 03/27/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 12:00:06 PM
- Incannex Healthcare Announces Partnership with the AASM Foundation in Support of Sleep Apnea Research • GlobeNewswire Inc. • 03/25/2026 12:00:00 PM
- Incannex says it holds $75 million in cash with zero debt after financing • IH Market News • 03/18/2026 02:24:59 PM
- Incannex Highlights Strong Balance Sheet with Approximately $75 Million in Cash and No Debt as Company Advances IHL-42X Development • GlobeNewswire Inc. • 03/18/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/17/2026 12:00:21 PM
- Incannex Regains Compliance with Nasdaq Minimum Bid Price Requirement • GlobeNewswire Inc. • 03/17/2026 12:00:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 03/12/2026 08:17:41 PM
- Incannex outlines dose-optimization study for sleep apnea treatment • IH Market News • 03/12/2026 03:42:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/12/2026 12:05:33 PM
- Incannex Healthcare Inc. Announces Pricing of $10 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules • GlobeNewswire Inc. • 03/12/2026 12:05:00 PM
- Incannex Strengthens Clinical Development Pathway for IHL-42X Following Positive Phase 2 Outcomes • GlobeNewswire Inc. • 03/12/2026 12:00:00 PM
- Incannex approves 1-for-30 reverse stock split to regain Nasdaq compliance • IH Market News • 02/25/2026 03:26:23 PM
- Incannex Announces Reverse Stock Split • GlobeNewswire Inc. • 02/25/2026 02:20:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 01:00:33 PM
- Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) 2Q 2026 • Newsfile • 02/18/2026 11:35:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/13/2026 12:48:45 PM
